Current Report Filing (8-k)
December 23 2016 - 12:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 21, 2016
pSivida Corp.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51122
|
|
26-2774444
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
480 Pleasant Street
Watertown, MA
|
|
02472
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617)
926-5000
(Former name
or former address, if changed since last report.)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On December 21, 2016, the Compensation Committee of the Board of
Directors of pSivida Corp. (the Company) approved Amended and Restated Performance-Based Restricted Stock Unit Award Agreements (the Restated Agreements) with each of Nancy Lurker and Deb Jorn. The Restated Agreements amended
and restated the Performance-Based Restricted Stock Unit Award Agreements, each dated November 2, 2016, between the Company and Ms. Lurker, on the one hand, and the Company and Ms. Jorn, on the other hand. The parties entered into the
Restated Agreements to amend certain of the vesting provisions therein to reflect the intent of the Compensation Committee at the time of the respective grants.
The foregoing description of the Restated Agreements is not complete and is qualified in its entirety by reference to the Restated Agreements,
which are filed as Exhibits 10.1 and 10.2 hereto and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
|
|
|
10.1
|
|
Amended and Restated Performance-Based Restricted Stock Unit Award Agreement, dated December 21, 2016, by and between pSivida Corp. and Nancy Lurker.
|
|
|
10.2
|
|
Amended and Restated Performance-Based Restricted Stock Unit Award Agreement, dated December 22, 2016, by and between pSivida Corp. and Deb Jorn.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
pSivida Corp.
|
|
|
|
|
Date: December 23, 2016
|
|
|
|
By:
|
|
/s/ Nancy Lurker
|
|
|
|
|
Name:
|
|
Nancy Lurker
|
|
|
|
|
Title
|
|
President and Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Document
|
|
|
10.1
|
|
Amended and Restated Performance-Based Restricted Stock Unit Award Agreement, dated December 21, 2016, by and between pSivida Corp. and Nancy Lurker.
|
|
|
10.2
|
|
Amended and Restated Performance-Based Restricted Stock Unit Award Agreement, dated December 22, 2016, by and between pSivida Corp. and Deb Jorn.
|
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024